SBANE possesses the necessary financial expertise to source capital for high technology and life science companies seeking liquidity from non-bank lenders to compliment their primary lender credit facility. Choices range from subordinated debt from quasi-public lenders to mezzanine options from non-bank alternatives, ranging from $500,000 to $5,000,000. We can provide your company with specific illustrations and frequency of transactions of companies we have helped.